Loading stock dataβ¦
$2.31+0.07 (+3.13%)
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
CervoMed Inc. in the Healthcare sector is trading at $2.31 with a market capitalization of $38M. Wall Street consensus targets $15.00 (5 analysts), implying a +549.4% move over the next 12 months. The stock is currently near its 52-week low of $2.13, remaining 36.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | β | β | β | β | β |
| Operating Income | -$6.68Mβ | -$8.11Mβ | -$8.33Mβ | -$8.04Mβ | -$6.62M |
| Net Income | -$6.57Mβ | -$7.96Mβ | -$8.09Mβ | -$7.73Mβ | -$6.26M |
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosse...